uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Exome-Based Rare-Variant Analyses in CKD
AstraZeneca, R&D BioPharmaceut, Discovery Sci, AstraZeneca Ctr Genom Res, Cambridge, England.
Columbia Univ, Dept Genet & Dev, New York, NY USA.
Columbia Univ, Dept Med, Div Nephrol, New York, NY USA.
AstraZeneca, R&D BioPharmaceut, Discovery Sci, AstraZeneca Ctr Genom Res, Cambridge, England.
Show others and affiliations
2019 (English)In: Journal of the American Society of Nephrology, ISSN 1046-6673, E-ISSN 1533-3450, Vol. 30, no 6, p. 1109-1122Article in journal (Refereed) Published
Abstract [en]

Background Studies have identified many common genetic associations that influence renal function and all-cause CKD, but these explain only a small fraction of variance in these traits. The contribution of rare variants has not been systematically examined. Methods We performed exome sequencing of 3150 individuals, who collectively encompassed diverse CKD subtypes, and 9563 controls. To detect causal genes and evaluate the contribution of rare variants we used collapsing analysis, in which we compared the proportion of cases and controls carrying rare variants per gene. Results The analyses captured five established monogenic causes of CKD: variants in PKD1, PKD2, and COL4A5 achieved study-wide significance, and we observed suggestive case enrichment for COL4A4 and COL4A3. Beyond known disease-associated genes, collapsing analyses incorporating regional variant intolerance identified suggestive dominant signals in CPT2 and several other candidate genes. Biallelic mutations in CPT2 cause carnitine palmitoyltransferase II deficiency, sometimes associated with rhabdomyolysis and acute renal injury. Genetic modifier analysis among cases with APOL1 risk genotypes identified a suggestive signal in AHDC1, implicated in Xia-Gibbs syndrome, which involves intellectual disability and other features. On the basis of the observed distribution of rare variants, we estimate that a two-to three-fold larger cohort would provide 80% power to implicate new genes for all-cause CKD. Conclusions This study demonstrates that rare-variant collapsing analyses can validate known genes and identify candidate genes and modifiers for kidney disease. In so doing, these findings provide a motivation for larger-scale investigation of rare-variant risk contributions across major clinical CKD categories.

Place, publisher, year, edition, pages
AMER SOC NEPHROLOGY , 2019. Vol. 30, no 6, p. 1109-1122
National Category
Urology and Nephrology
Identifiers
URN: urn:nbn:se:uu:diva-390637DOI: 10.1681/ASN.2018090909ISI: 000474779900019PubMedID: 31085678OAI: oai:DiVA.org:uu-390637DiVA, id: diva2:1344618
Funder
AstraZenecaAvailable from: 2019-08-21 Created: 2019-08-21 Last updated: 2019-08-21Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Fellström, Bengt

Search in DiVA

By author/editor
Fellström, Bengt
By organisation
Renal Medicine
In the same journal
Journal of the American Society of Nephrology
Urology and Nephrology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 30 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf